SCHEMBL3205630

SCHEMBL3205630

O=C(O)c1ccc(Cl)c(-c2ccc(-c3ccccc3)cc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.55
KMO O15229 1/20 0.52
EGFR P00533 1/20 0.51
LTB4R Q15722 1/20 0.51
MAP4K4 O95819 2/20 0.50
MAPT P10636 2/20 0.50
RXRA P19793 1/20 0.50
RXRB P28702 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PRKAB2 O43741 1/20 0.50
PRKAG1 P54619 1/20 0.50
PRKAA2 P54646 1/20 0.50
PRKAA1 Q13131 1/20 0.50
PRKAG3 Q9UGI9 1/20 0.50
PRKAG2 Q9UGJ0 1/20 0.50
PRKAB1 Q9Y478 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
CTRC Q99895 1/20 0.49
SRD5A2 P31213 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3200062 0.96 TSHR (0.59) TSHRKMOLTB4RMAPTRXRA
SCHEMBL6254017 0.91 TSHR (0.61) TSHRKMOMAP4K4MAPTRXRA
SCHEMBL3211804 0.90 KMO (0.62) TSHRKMOEGFRLTB4RMAP4K4
SCHEMBL3199834 0.88 TSHR (0.53) TSHREGFRMAPTRXRARXRB
SCHEMBL3216304 0.88 EGFR (0.51) TSHRKMOEGFRRXRARXRB
SCHEMBL3210915 0.86 AKR1C3 (0.47) TSHRMAPTMEN1KMT2ASRD5A2
SCHEMBL3207912 0.86 TSHR (0.55) TSHRKMOMAPTRXRARXRB
SCHEMBL3220340 0.86 TSHR (0.55) TSHRKMOMAPTRXRARXRB
SCHEMBL3208925 0.85 BCL2 (0.55) TSHRKMOMAPTRXRARXRB
SCHEMBL3214594 0.85 MKNK1 (0.68) KMOMAP4K4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683097-B2 Topoisomerase inhibitors Propharmacon Inc. (US) 2010-03-23 US claimed
US-7683097-B2 Topoisomerase inhibitors Propharmacon Inc. (US) 2010-03-23 US disclosed
US-7683097-B2 Topoisomerase inhibitors Propharmacon Inc. (US) 2010-03-23 US disclosed
US-7683097-B2 Topoisomerase inhibitors Propharmacon Inc. (US) 2010-03-23 US disclosed
US-20070004701-A1 Topoisomerase inhibitors PROPHARMACON, INC. (US) 2007-01-04 US disclosed
US-20070004701-A1 Topoisomerase inhibitors PROPHARMACON, INC. (US) 2007-01-04 US disclosed
US-20070004701-A1 Topoisomerase inhibitors PROPHARMACON, INC. (US) 2007-01-04 US disclosed
WO-2006022955-A2 TOPOISOMERASE INHIBITORS PROPHARMACON, INC. (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004701-A1 Topoisomerase inhibitors TOP1, TOP2A, TOP2B TSHR 4456/4885KMO 3110/4885EGFR 3486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.